GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT01061775

CompletedPhase 1, PHASE2Results posted

Effects of Exenatide on Hypothalamic Obesity

Lead sponsor

Children's Hospitals and Clinics of Minnesota

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Hypothalamic / syndromic obesity, Obesity / overweight

Key I/E criterion

—

Primary endpoints

•BMI, change•Waist to Height Ratio (WHtR)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01061775

Org study ID0903-028

Timeline

Milestones

Study first posted2010-02-03estimated

Results first posted2016-03-21estimated

Study completion2019-03-15actual

Last update posted2019-10-08actual

Study start2010-01 (month precision)

Primary completion2013-07actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Hypothalamic / syndromic obesityObesity / overweight

Eligibility

Who can enroll

Minimum age10 Years

Maximum age21 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•>/=6 months post surgical or radiation or chemotherapy treatment for 1° craniopharyngiomas or other suprasellar tumors

•10-21 years old

•Age-and sex-adjusted BMI >/=95%

•Parent sign consent and patient sign assent

Exclusion criteria

•< 6 months post surgical or radiation or chemotherapy treatment for 1° craniopharyngiomas or other suprasellar tumors

•Pregnant or breastfeeding, or those women who plan to get pregnant

•Renal impairment

•Gastroparesis

•Pancreatitis

•Diabetes

•<1 month post initiation of Metformin treatment

•Prescription or over-the-counter weight loss medications within 3 months of screening

•Are actively participating in, or have participated in a formal weight loss program within the last 3 months

•Have had bariatric surgery

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Patient-reported / QoL

Other clinical outcomes

Weight & body composition

2 endpoints

Primary/protocol endpoint

BMI Change

Time frame:24 weeks

BMI, change

change from baseline, improvement

Posted result

Group	Value (mean), kg/m^2	95% CI
Exenatide	-0.77	-1.97 – 0.43

p.05t-test, 2 sided

Primary/protocol endpoint

Waist to Height Ratio (WHtR)

Time frame:24 weeks

ratio, improvement

Posted result

Group	Value (mean), percentage	95% CI
Exenatide	-2.06	—

p0.05t-test, 2 sided

Patient-reported / QoL

1 endpoint

Secondary/protocol endpoint

Childhood Eating Behavior Questionnaire (CEBQ)

Time frame:24 weeks

change from baseline, improvement

Posted result

Group	Value (mean), units on a scale	95% CI
Exenatide	14	12.2167 – 15.7833

p0.05t-test, 2 sided

Other clinical outcomes

1 endpoint

Secondary/protocol endpoint

Calorie Intake Based on 3-day Diet Records

Time frame:24 weeks

change from baseline, improvement

Posted result

Group	Value (mean), kcals	95% CI
Exenatide	406.700	-117.088 – 930.488

p0.05t-test, 2 sided

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.